The activity of the human drug-metabolizing enzyme cytochrome P450 3A4 (hCYP3A4) can seriously compromise the therapeutic effect of several drugs. Although CYP3A4 inhibitors may improve the in vivo efficacy of hCYP3A4-substrate drugs, most of them trigger serious adverse effects.